State of the art in breast intraoperative electron radiation therapy after intraoperative ultrasound introduction
, , , , , , , , , et
16 mai 2021
À propos de cet article
Catégorie d'article: Research Article
Publié en ligne: 16 mai 2021
Pages: 333 - 340
Reçu: 12 nov. 2020
Accepté: 06 avr. 2021
DOI: https://doi.org/10.2478/raon-2021-0023
Mots clés
© 2021 Cristiana Vidali, Mara Severgnini, Gabriele Bellio, Fabiola Giudici, Vittorino Milan, Zaira Pellin, Sara Savatovic, Serena Scomersi, Gerd Fastner, Antonella Ciabattoni, Marina Bortul, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Figure 1
Figure 2A
Figure 2B
Figure 3
Acute toxicity of radiotherapy in the two groups
| Group 1 (n = 38) | Group 2 (n = 72) | Total (n = 110) | |
|---|---|---|---|
| 23 (60.5%) | 36 (50%) | 59 (53.6%) | |
| 8 (21.1%) | 28 (38.9%) | 36 (32.7%) | |
| 6 (15.8%) | 7 (9.7%) | 13 (11.8%) | |
| 1 (2.6%) | 1 (1.4%) | 2 (1.9%) | |
| 14 (36.8%) | 35 (48.6%) | 49 (44.5%) |
Late toxicity of radiotherapy in the two groups
| Group 1 (n = 38) | Group 2 (n = 72) | Total (n = 110) | |
|---|---|---|---|
| 22 (57.9%) | 43 (59.7%) | 65 (59.1%) | |
| 12 (31.6%) | 24 (33.3%) | 36 (32.7%) | |
| 3 (7.9%) | 3 (4.2%) | 6 (5.5%) | |
| 1 (2.6%) | 2 (2.8%) | 3 (2.7%) | |
| 15 (39.5%) | 27 (37.5%) | 42(38.2%) |
Description of the population
| Variables | All cohort (n = 110) | Group 1 (n = 38) | Group 2 (n = 72) | p-value |
|---|---|---|---|---|
| Age (years) Median (range) | 67 (43−85) | 67 (48−80) | 67 (43−85) | p = 0.51 |
| Clinical stage | ||||
| cT1a N0 | 2 (1.8%) | 1 (2.6%) | 1 (1.4%) | |
| cT1b N0 | 47 (42.8%) | 20 (52.6%) | 27 (37.5%) | |
| cT1c N0 | 59 (53.6%) | 17 (44.8%) | 42 (58.3%) | p = 0.42 |
| cT1b N1 | 1 (0.9%) | 0 (0.0%) | 1 (1.4%) | |
| cT2 N0 | 1 (0.9%) | 0 (0.0%) | 1 (1.4%) | |
| Histological type | ||||
| Ductal carcinoma in situ (DCIS) | 1 (0.9%) | 1 (2.6%) | 0 (0.0%) | |
| Invasive ductal carcinoma | 70 (63.6%) | 26 (68.4%) | 44 (61.1%) | p = 0.46 |
| Invasive lobular carcinoma | 19 (17.3%) | 5 (13.2%) | 14 (19.45%) | |
| Others | 20 (18.2%) | 6 (15.8%) | 14 (19.45%) | |
| Multifocal disease | 6 (5.4%) | 4 (10.5%) | 2 (2.8%) | p = 0.21 |
| Pathological Stage pT | ||||
| pTis | 1 (0.9%) | 1 (2.6%) | 0 (0.0%) | |
| pT1a | 3 (2.7%) | 0 (0.0%) | 3 (4.2%) | |
| pT1b | 41 (37.3%) | 16 (42.1%) | 25 (34.7%) | p=0.40 |
| pT1c | 59 (53.6%) | 20 (52.6%) | 39 (54.2%) | |
| pT2 | 6 (5.5%) | 1 (2.6%) | 5 (6.9%) | |
| Pathological Stage pN | ||||
| pN0 | 88 (80.0%) | 32 (84.2%) | 56 (77.8%) | |
| pN1mi | 7 (6.4%) | 3 (7.9%) | 4 (5.6%) | p=0.71 |
| pN1a | 14 (12.7%) | 3 (7.9%) | 11 (15.3%) | |
| pN3 | 1 (0.9%) | 0 (0.0%) | 1 (1.4%) | |
| Grading | ||||
| G1 | 15 (13.7%) | 7(18.4%) | 8 (11.1%) | |
| G2 | 68 (61.8%) | 24 (63.2%) | 44 (61.1%) | p = 0.67 |
| G3 | 21 (19.1%) | 6 (15.8%) | 15 (20.8%) | |
| Gx | 6 (5.4%) | 1 (2.6%) | 5 (7%) | |
| Adjuvant therapy Calculated on 109 patients |
||||
| None | 2 (1.8%) | 0 (0.0%) | 2 (2.8%) | |
| Chemotherapy | 6 (5.5%) | 2 (5.4%) | 4 (5.6%) | p = 0.92 |
| Endocrine therapy | 85 (78%) | 29 (78.4%) | 56 (77.7%) | |
| Chemotherapy + Endocrine therapy | 12 (11%) | 4 (10.8%) | 8 (11.1%) | |
| Chemotherapy + Trastuzumab | 4 (3.7%) | 2 (5.4%) | 2 (2.8%) |